youtube_live
Q3 2026 earnings • released • EPS beat +23.93% • Revenue beat +12.14%
See resultschevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$961.26
arrow_upward
+3.60%(+33.37) 1D
$967.89
arrow_upward
+0.69% (+6.63)bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$927.22
High
$974.00
Low
$927.00
Mkt. cap
98.97B
Avg. vol.
753.59K
Volume
1.66M
Dividend
0.39%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
23.77
52-wk high
$974.00
52-wk low
$591.52
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$927.22
High
$974.00
Low
$927.00
Mkt. cap
98.97B
Avg. vol.
753.59K
Volume
1.66M
Dividend
0.39%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
23.77
52-wk high
$974.00
52-wk low
$591.52
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
Yahoo Finance
·
1 hour ago
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts
GuruFocus
·
7 hours ago
REGN Maintained by Bernstein -- Price Target Raised to $812
www.marketscreener.com
·
10 hours ago
Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says
Investing.com
·
12 hours ago
Cantor Fitzgerald raises Regeneron stock price target on Dupixent strength
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Analyst ratings
Based on 24 analysts giving stock ratings to REGN in the past 3 months
Buy
Buy
16
Hold
8
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for REGN in the last 3 months.
Highest
Current $961.26
$1,175.00 (+22.24%)
Average
$952.75 (-0.89%)
Lowest
$770.00 (-19.90%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Risinger Leerink Partners | Hold | Maintained | $997.00 | +3.7% | 11/02/2026 |
Joon Lee UBS | Buy | Maintained | $1,068.00 | +11.1% | 11/02/2026 |
William Pickering Bernstein | Hold | Maintained | $812.00 | -15.5% | 11/02/2026 |
Gregory Renza Truist Financial | Buy | Maintained | $982.00 | +2.2% | 11/02/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | $980.00 | +1.9% | 11/02/2026 |
Yatin Suneja Guggenheim | Buy | Maintained | $1,100.00 | +14.4% | 11/02/2026 |
John Newman Canaccord Genuity | Buy | Maintained | $1,175.00 | +22.2% | 11/02/2026 |
Brian Skorney Robert W. Baird | Hold | Reiterated | $875.00 | -9% | 11/02/2026 |
Terence Flynn Morgan Stanley | Hold | Reiterated | $855.00 | -11.1% | 11/02/2026 |
Geoff Meacham Citi | Hold | Maintained | $825.00 | -14.2% | 11/02/2026 |
Biren Amin Piper Sandler | Buy | Maintained | $1,000.00 | +4% | 10/30/2026 |
Chris Schott J.P. Morgan | Buy | Maintained | $1,050.00 | +9.2% | 10/30/2026 |
Christopher Raymond Raymond James | Buy | Maintained | $1,020.00 | +6.1% | 10/30/2026 |
Brian Abrahams RBC Capital | Hold | Reiterated | $913.00 | -5% | 10/30/2026 |
Mohit Bansal Wells Fargo | Hold | Maintained | $925.00 | -3.8% | 10/30/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $1,030.00 | +7.2% | 10/30/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | $980.00 | +1.9% | 10/21/2026 |
Unknown Analyst UBS | Buy | Upgraded | $978.00 | +1.7% | 10/14/2026 |
Louise Chen Scotiabank | Hold | Maintained | $770.00 | -19.9% | 10/14/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $920.00 | -4.3% | 10/12/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $972.00 | +1.1% | 10/01/2026 |
Eliana Merle Barclays | Buy | Maintained | $917.00 | -4.6% | 10/02/2026 |
Akash Tewari Jefferies | Buy | Maintained | $930.00 | -3.3% | 10/01/2026 |
Jasper Hellweg Argus Research | Buy | Upgraded | $850.00 | -11.6% | 09/30/2026 |
Eve Burstein Bernstein | Hold | Maintained | $756.00 | -21.4% | 09/25/2026 |
Rajesh Kumar HSBC | Buy | Maintained | $920.00 | -4.3% | 09/10/2026 |
Alexandria Hammond Wolfe Research | Buy | Reiterated | $860.00 | -10.5% | 05/18/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $825.00 | -14.2% | 05/18/2026 |
Nicholas Lorusso TD Cowen | Buy | Maintained | $960.00 | -0.1% | 05/06/2026 |
Matthew Biegler Oppenheimer | Buy | Reiterated | $865.00 | -10% | 04/30/2026 |
Last report
Oct 30, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$20.07 / $16.19
+23.93%beat
arrow_upward
Revenue / Est. (USD)
5.12B / 4.56B
+12.14%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 3.88B | 3.61B | 4.29B | 5.12B |
Cost of goods sold | 2.21B | 2.21B | 2.21B | 2.37B |
Cost of revenue | 2.21B | 2.21B | 2.21B | 2.37B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 775.00M | 647.70M | 662.10M | 677.80M |
Operating expense | 775.00M | 647.70M | 662.10M | 677.80M |
Total operating expenses | 2.99B | 2.86B | 2.87B | 3.05B |
Operating income | 898.60M | 744.80M | 1.42B | 2.07B |
Other non operating income | 958.50M | -7.30M | 100.00K | 4.40M |
EBT including unusual items | 1.04B | 831.20M | 1.53B | 2.28B |
EBT excluding unusual items | 2.04B | 908.10M | 1.59B | 2.25B |
Income tax expense | 199.10M | 104.00M | 230.90M | 335.40M |
Effective tax rate | 19.08% | 12.51% | 15.11% | 14.68% |
Other operating expenses | - | - | - | - |
Net income | 844.60M | 727.20M | 1.30B | 1.95B |
Net profit margin | 21.74% | 20.17% | 30.23% | 38.09% |
Earnings per share | 11.44 | 9.47 | 14.29 | 20.07 |
Interest and investment income | 193.30M | 183.50M | 183.30M | 181.80M |
Interest expense | -12.20M | -12.90M | -11.00M | -10.60M |
Net interest expenses | 181.10M | 170.60M | 172.30M | 171.20M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.04B | 868.00M | 1.54B | 2.19B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events